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IMPORTANCE Abnormal peripheral perfusion after septic shock resuscitation has been
associated with organ dysfunction and mortality. The potential role of the clinical
assessment of peripheral perfusion as a target during resuscitation in early septic shock
has not been established.
OBJECTIVE To determine if a peripheral perfusion–targeted resuscitation during early
septic shock in adults is more effective than a lactate level–targeted resuscitation for
reducing mortality.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized trial conducted at 28 intensive
care units in 5 countries. Four-hundred twenty-four patients with septic shock were included
between March 2017 and March 2018. The last date of follow-up was June 12, 2018.
INTERVENTIONS Patients were randomized to a step-by-step resuscitation protocol aimed
at either normalizing capillary refill time (n = 212) or normalizing or decreasing lactate levels
at rates greater than 20% per 2 hours (n = 212), during an 8-hour intervention period.
MAIN OUTCOMES AND MEASURES The primary outcome was all-cause mortality at 28 days.
Secondary outcomes were organ dysfunction at 72 hours after randomization, as assessed by
Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death
within 90 days; mechanical ventilation–, renal replacement therapy–, and vasopressor-free
days within 28 days; intensive care unit and hospital length of stay.
RESULTS Among 424 patients randomized (mean age, 63 years; 226 [53%] women),
416 (98%) completed the trial. By day 28, 74 patients (34.9%) in the peripheral perfusion
group and 92 patients (43.4%) in the lactate group had died (hazard ratio, 0.75 [95% CI,
0.55 to 1.02]; P = .06; risk difference, −8.5% [95% CI, −18.2% to 1.2%]). Peripheral
perfusion–targeted resuscitation was associated with less organ dysfunction at 72 hours
(mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, −1.00 [95% CI, −1.97 to
−0.02]; P = .045). There were no significant differences in the other 6 secondary outcomes.
No protocol-related serious adverse reactions were confirmed.
CONCLUSIONS AND RELEVANCE Among patients with septic shock, a resuscitation strategy
targeting normalization of capillary refill time, compared with a strategy targeting serum
lactate levels, did not reduce all-cause 28-day mortality.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03078712
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E arly resuscitation is a key factor to limit progression tomultiple organ dysfunction and death in patients withseptic shock.1,2 Shock is characterized by increased se-
rum lactate levels and signs of tissue hypoperfusion includ-
ing abnormal peripheral perfusion.2
Considering the strong relationship between hyperlac-
tatemia, lactate kinetics, and mortality,3 and the results of a
recent study,4 the Surviving Sepsis Campaign, proposes to
guide hemodynamic resuscitation by repeated measurement
of blood lactate levels every 2 to 4 hours until normalization.5
However, persistent hyperlactatemia may be related to causes
other than tissue hypoperfusion,6 lactate kinetics is rela-
tively slow even in survivors,3,7 and measurements of lactate
levels may not be universally available. Therefore, the explo-
ration of alternative resuscitation targets is an important re-
search priority in sepsis.8
Observational studies have shown that persistent abnor-
mal peripheral perfusion after resuscitation is associated with
organ failure9 and mortality.10 Capillary refill time (CRT) is an
easy-to-use, resource-independent method to assess periph-
eral perfusion.11,12 CRT has been shown to rapidly respond to
resuscitation,7,13 and its assessment might be effectively used
to allow adjustments of therapy.14
Consequently, a multicenter randomized clinical trial
comparing peripheral perfusion–targeted resuscitation to
lactate level–targeted resuscitation in patients with early
septic shock was conducted, hypothesizing that resuscita-
tion guided by peripheral perfusion would be associated
with improved outcomes.
Methods
Study Design and Oversight
The ANDROMEDA-SHOCK randomized clinical trial was con-
ducted at 28 hospitals in 5 countries (Argentina, Chile,
Colombia, Ecuador, Uruguay). The institutional review board
at each site approved the study. Written informed consent was
obtained from all patients or surrogates. The protocol and sta-
tistical analysis plan have been previously published15,16 and
are available in Supplement 1. The trial was logistically sup-
ported by the Pontificia Universidad Católica of Chile.
The members of the steering committee designed the trial
and analyzed the data. The data and safety monitoring com-
mittee oversaw the trial. The steering committee vouches for
the accuracy of the data and adherence to the study protocol.
Patient Selection and Randomization
Consecutive adult patients (≥18 years) with septic shock ad-
mitted to the intensive care unit (ICU) were considered eli-
gible. Septic shock was defined as suspected or confirmed in-
fection, plus hyperlactatemia (≥2.0 mmol/L) and requirements
of vasopressors to maintain a mean arterial pressure (MAP) of
65 mm Hg or higher after an intravenous fluid load of at least
20 mL/kg over 60 minutes.17 Patients were recruited within 4
hours after fulfilling criteria. Exclusion criteria included bleed-
ing, severe acute respiratory distress syndrome, and do-not-
resuscitate status (Supplement 1).
Eligible patients were randomly allocated to peripheral per-
fusion–targeted resuscitation (peripheral perfusion) or lac-
tate level–targeted resuscitation (lactate) groups. A random-
ization sequence by permuted blocks of 8 with an allocation
of 1:1 was generated by a computer program. Allocation con-
cealment was maintained by means of central randomiza-
tion. Investigators called a representative of the study coor-
dinating center, who was available via a dedicated telephone
line. Group allocation was only disclosed after the informa-
tion was centrally checked and recorded.
Study Interventions
The intervention period was 8 hours. Before starting the study,
all centers were trained to assess capillary refill time with a stan-
dardized technique.15 Briefly, CRT was measured by applying
firm pressure to the ventral surface of the right index finger
distal phalanx with a glass microscope slide. The pressure was
increased until the skin was blank and then maintained for 10
seconds. The time for return of the normal skin color was reg-
istered with a chronometer, and a refill time greater than 3 sec-
onds was defined as abnormal.
For assessment of fluid responsiveness,18 each center used
their standard technique when feasible and an additional al-
gorithm was provided for difficult cases15 (Supplement 1).
Lactate level was assessed every 2 hours.5 CRT was evalu-
ated every 30 minutes, because of its faster rate of recovery,7,19
until normalization and then every hour during the interven-
tion period.
The goal for the peripheral perfusion group was to nor-
malize CRT, whereas the goal for the lactate group was to nor-
malize or to decrease lactate levels by 20% every 2 hours.
After initial fluid resuscitation and norepinephrine to main-
tain a MAP of 65 mm Hg or higher, both groups were man-
aged with an identical sequential protocolized approach to re-
suscitation (eFigure 1 in Supplement 2).1,2
The first step was assessment of fluid responsiveness,18
followed by fluid challenges with 500 mL of crystalloids
every 30 minutes in fluid responders until the goal was
achieved as assessed at intervals depending on the allocated
group, a central venous pressure safety limit was reached,20
or the patient became fluid unresponsive, whichever came
first. In patients in whom fluid responsiveness could not be
Key Points
Question Does the use of a resuscitation strategy targeting
normalization of capillary refill time, compared with a strategy
targeting serum lactate levels, reduce mortality among patients
with septic shock?
Findings In this randomized clinical trial of 424 patients with early
septic shock, 28-day mortality was 34.9% in the peripheral
perfusion–targeted resuscitation group compared with 43.4% in
the lactate level–targeted resuscitation group, a difference that
did not reach statistical significance.
Meaning These findings do not support the use of a peripheral
perfusion–targeted resuscitation strategy in patients with
septic shock.
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determined, fluid resuscitation was continued until the goal
was met or a safety limit was reached.
In patients with chronic hypertension,1,2,21 if the previ-
ous interventions did not meet the goals, a vasopressor test
was conducted, transiently increasing norepinephrine dose un-
til reaching a MAP of 80 to 85 mm Hg, followed by a reassess-
ment of CRT or lactate level after 1 or 2 hours, respectively. If
the goal was met, this MAP level was maintained throughout
the intervention period. Otherwise, norepinephrine was de-
creased to the previous dose and the patient moved to the next
step, similar to patients without chronic hypertension with per-
sistent hypoperfusion.
The third step consisted of an inodilator test with low-
dose dobutamine or milrinone (depending on local proto-
cols) if the target was still not reached.1 Patients were again re-
assessed after 1 or 2 hours in the peripheral perfusion and
lactate groups, respectively. If the end points were still not met
or a safety issue arose,15 the inodilator was discontinued.
A distinctive characteristic of the protocol was that when
required, higher MAP targets or inodilators were introduced
as a test, meaning that the effect was reassessed after a short
period and the interventions maintained only in responders.
Investigators were recommended to follow Surviving
Sepsis Campaign guidelines for background, refractory
shock, and source control management.1 Other monitoring
and interventions during and after the intervention period
could be used in both groups at the discretion of the attend-
ing physicians.
Resuscitation, Perfusion, and Hemodynamic Variables
Data were collected on several perfusion and hemodynamic
variables, listed in eTable 2 in Supplement 2 during the first
72 hours after randomization.
Outcome Measures
The primary outcome was all-cause mortality at 28 days.
Secondary prespecified outcomes were death within 90
days; organ dysfunction during the first 72 hours after ran-
domization (assessed by Sequential Organ Failure Assess-
ment [SOFA] score, with higher scores indicating a greater
severity of organ dysfunction in critically ill patients),22
mechanical ventilation–free days within 28 days; renal
replacement therapy–free days within 28 days; vasopressor-
free days within 28 days; and ICU and hospital length
of stay. Patients who died were assigned zero free days.
Mechanical ventilation–free days, renal replacement–free
days, or vasopressor-free days within 28 days were defined
as the number of days alive and without use of the specific
supportive therapy from randomization to day 28. Tertiary
prespecified exploratory outcomes were resuscitation fluids
during the intervention period; total fluid balance within 8,
24, and 72 hours ; occurrence of intra-abdominal hyperten-
sion within 72 hours; use of renal replacement therapy
within 28 days; and in-hospital mortality.16
A rigorous methodology was developed to reduce loss
to follow-up. The true survival state at days 28 or 90 (either
in or outside the hospital at that day) was determined. For
patients still hospitalized at days 28 or 90, actual status was
gathered from hospital registers. Hospital mortality was
truncated at the date of the database lock (June 12, 2018).
For patients discharged before the critical outcome dates,
follow-ups were performed by telephone calls previously
announced during the informed consent process or by con-
sulting potential death status in the national civil register or
the specific health system registry, depending on the coun-
try. Electronic reminders were sent to centers before the
critical dates.
Data also were collected on cases of suspected unex-
pected serious adverse reactions, defined as any adverse
event reported by study investigators for being unexpected,
serious, and having a reasonable possibility of a causal rela-
tionship with the study procedures. These reports were ana-
lyzed by the study coordinating center together with local
investigators, and its relationship with the study protocol
was determined.
Statistical Analysis
We planned to enroll 420 patients. We calculated that with this
sample size the study would have 90% power to detect a re-
duction in 28-day mortality from 45% in the lactate group to
30% in the peripheral perfusion group,4,10,11 at an α level of .05.
Interim analyses after the inclusion of the first 100 and 300
patients were performed by the data and safety monitoring
committee, which had no preestablished formal stopping rules.
After both analyses the committee recommended to con-
tinue the trial without alterations.
We compared resuscitation, perfusion, and hemody-
namic categorical variables between treatment groups with
Fisher exact tests. For continuous variables, generalized lin-
ear mixed models with different distributions were used:
Gaussian distribution was used for heart rate, central venous
oxygen saturation, and systolic, diastolic, and mean arterial
blood pressures; gamma distribution was used for norepi-
nephrine dose, diuresis, lactate level, CRT, and central venous–
arterial PCO2 gradient; binomial (logistic model) was used for
norepinephrine use.
The treatment effect on the primary outcome was calcu-
lated with Cox proportional hazards, with adjustment
for 5 prespecified baseline covariates: Acute Physiology
and Chronic Health Evaluation (APACHE) II score,23
SOFA score,24 lactate level, CRT, and source of infection.
The proportional hazards assumption was tested with the
Grambsch and Therneau method.25 Results are reported as
hazard ratio with 95% confidence interval and as Kaplan-
Meier curves.
The effect on 90-day all-cause mortality was assessed
with Cox proportional hazards model. Other binary second-
ary and tertiary outcomes were tested using Fisher exact
tests. Treatment effect on mechanical ventilation–free days,
renal replacement therapy–free days, and vasopressor-free
days within 28 days was analyzed by zero-inflated negative
binomial models. ICU and hospital length of stay and resus-
citation fluids were assessed with generalized linear models
with gamma distribution. Fluid balance was compared with
linear regression. The treatment effect on organ dysfunction
at 72 hours was evaluated with linear regression adjusting
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for baseline SOFA score. As a post hoc analysis, we com-
pared SOFA values measured during the 72 hours (at 8, 24,
48, and 72 hours) between treatment groups using a mixed
linear regression model, with adjustment for baseline SOFA
score, considering time as a continuous variable, patient as
random effect, and a treatment × time interaction term.
Analyses of secondary or tertiary outcomes were not
adjusted for covariates.
A prespecified sensitivity analysis was performed using
a frailty Cox model with sites as random effects, assuming a
gamma distribution, adjusted for the same covariates as in
the main model—results were presented as marginal effects.
Frailty models account for the possible heterogeneity of
treatment effects across trial sites. Subgroup analyses,
with Cox proportional hazards adjusted for the same
covariates as in the main model, were conducted to assess
interactions between treatment effect and the following
prespecified baseline characteristics: lactate levels (>4.0 vs
≤4.0 mmol/L); APACHE II score (<25 vs ≥25); SOFA score
(<10 vs ≥10); source of infection (confirmed vs uncon-
firmed); variation of lactate level between first measure-
ment and baseline measurement (≥10% vs <10%).16 Several
additional post hoc sensitivity analyses listed in the
eMethods in Supplement 2, including per protocol analyses,
were performed. Furthermore, in a post hoc analysis, we
assessed whether treatment effect on the primary outcome
might differ across sites using a Cox proportional hazards
model adjusted for the same covariates as the main model
and a treatment × site interaction term.
Patients were analyzed according to randomization
group, except when indicated otherwise. All hypothesis
tests were 2-sided, with a significance level of .05 and no
adjustments for the interim analyses, multiple outcomes,
or subgroup analyses. Therefore, analyses of secondary
outcomes and other outcomes should be considered explor-




From March 2017 through March 2018, 1327 patients were
assessed for eligibility (Figure 1). A total of 424 patients
were enrolled (mean age, 63 years; 226 [53%] women),
with 212 assigned to each group (Figure 1; eFigure 2 and
eTable 1 in Supplement 2). Data for the primary and second-
ary outcomes were obtained for all patients. All patients
were included in the intention-to-treat analysis for the pri-
mary outcome.
Baseline patient characteristics were similar (Table 1).
Seventy-one percent of the patients were admitted from the
emergency department, 17% from wards, 7% from step-
down units, and 5% directly from the operating room.
Figure 1. Flow of Participants Through the Study
1327 Patients assessed for eligibility
903 Excluded
801 Ineligible
102 Eligible but not enrolled
109 Do-not-resuscitate status
106 Acute hematologic emergency
70 Severe acute respiratory distress syndrome
9 Lack of consent




1 Age <18 y
286 More than 4 h after meeting septic shock criteria
208 Anticipated surgery or dialysis in next 8 h
424 Randomized
212 Randomized to receive peripheral
perfusion–targeted resuscitation
207 Received intervention as
randomized
5 Did not receive intervention
as randomized
4 Lack of personnel
1 Unexpected surgery
212 Randomized to receive lactate
level–targeted resuscitation
209 Received intervention as
randomized
3 Did not receive intervention
as randomized
2 Lack of personnel
1 Malfunction of point-of-care
lactate assessment device
212 Included in primary outcome analysis 212 Included in primary outcome analysis
0 Lost to 28-d follow-up 0 Lost to 28-d follow-up
a Among the 87 patients eligible but
not enrolled because of other
reasons, 55 were not enrolled
because of logistic issues (lack of
personnel, multiple simultaneous
admissions) and 32 because of delay
in transfer from the emergency
department to the intensive care
unit after meeting criteria and then
losing the window of intervention.
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Adherence to the Protocol
Lack of adherence was registered in 29 patients (13.7%) in
the peripheral perfusion group and 23 (10.8%) in the lactate
group (eTable 3 in Supplement 2). Most of these instances
were protocol deviations (26 in the peripheral perfusion
group and 20 in the lactate group), and 8 patients did not
receive the assigned intervention. Protocol deviations were
protocol mismanagement in 16 instances in each group, and
early termination of assigned treatment for refractory shock
in 8 instances in the peripheral perfusion group and 4
instances in the lactate group.
Resuscitation, Perfusion, and Hemodynamic Variables
Two-hundred forty-two patients (57%) were fluid responsive
and 106 (25%) fluid unresponsive at baseline, without differ-
ences between groups. Fluid responsiveness could not be de-
termined in 76 patients (18%). The most frequently used tech-
niques were pulse pressure variation and passive leg raising
with velocity time integral determination in 144 patients in each
group. Evolution of fluid responsiveness during the interven-
tion period is shown in eFigure 3 in Supplement 2.
Fewer patients in the peripheral perfusion group (28.8%)
than in the lactate group (40.1%) required a vasopressor test










Age, mean (SD), y 62 (17) 64 (17)
Sex, No. (%)
Men 108 (50.9) 90 (42.5)
Women 104 (49.1) 122 (57.5)
Charlson Comorbidity Index,
median (IQR)b
3 (1-5) 3 (1-5)
APACHE II, mean (SD)c 21.9 (8.0) 22.0 (7.6)
SOFA, mean (SD)d 9.7 (3.4) 9.6 (3.5)
Chronic hypertension, No. (%) 83 (39.2) 93 (43.9)
Confirmed microbiology, No. (%) 151 (71.2) 153 (72.2)
Septic shock source, No. (%)
Intra-abdominal infection 72 (34.0) 77 (36.3)
Pneumonia 70 (33.0) 58 (27.4)
Urinary tract infection 42 (19.8) 45 (21.2)
Other sourcese 18 (8.5) 19 (9.0)
Unknown origin 10 (4.7) 13 (6.1)
Hemodynamic and perfusion-related
variables
Heart rate, mean (SD), /min 103 (24) 104 (23)
Arterial blood pressure,
mean (SD), mm Hg
69 (14) 68 (13)
Norepinephrine dose,
median (IQR), μg/kg/min
0.24 (0.11-0.40) 0.20 (0.10-0.35)
Central venous pressure, No. 199 194
Median (IQR), mm Hg 9 (6-13) 9 (6-12)
Serum lactate, mean (SD), mmol/L 4.6 (4.3) 4.5 (2.5)
Central venous oxygen saturation, No. 204 197
Mean (SD) 71 (13) 71 (12)
Venous-arterial PCO2 gradient, No. 203 195
Median (IQR), mm Hg 7 (5-10) 7 (5-10)
Capillary refill time
Median (IQR), s 5 (4-6) 4 (3-6)
≤3 s, No. (%) 48 (22.6) 60 (28.3)
Initial management data,
median (IQR)
Time from matching entry criteria
to randomization, h
1.5 (0.0-3.0) 1.3 (0.0-2.6)
Intravenous fluid loading per weight,
mL/kgf
25 (16-40) 30 (20-43)
Time from diagnosis of septic shock
to antibiotics, h
2.0 (1.0-2.0) 1.5 (1.0-2.0)
Abbreviations: APACHE, Acute
Physiology and Chronic Health
Evaluation; IQR, interquartile range;
SOFA, Sequential Organ Failure
Assessment.
a For variables with missing data,
summary data are based on
available cases.
b Range, 0 to 33; higher scores
indicate a greater burden of disease.
c Range, 0 to 71; higher scores
indicate greater severity of illness
and risk of in-hospital death
(eg, a score of 22 in a medical
patient with sepsis predicts an
in-hospital mortality of 45%).22
d Range, 0 to 24; higher scores
indicate a greater severity of organ
dysfunction in critically ill patients
and risk of in-hospital death
(eg, a score of 10 predicts an
in-hospital mortality of 50%).22
e Other sources of infection were
soft-tissue infection (n = 18),
meningitis (n = 6), central
line–associated bloodstream
infection (n = 4), endocarditis
(n = 2), mediastinitis (n = 2), herpes
encephalitis (n = 1), subdural
empyema (n = 1), pleural empyema
(n = 1), septic arthritis (n = 1),
and septic abortion (n = 1).
f Total intravenous fluids include
fluids administered during the
interval between presentation
to the emergency department
and randomization.
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(difference, −11.3% [95% CI, −20.8% to −1.9%]; P = .02)
(eTable 4 in Supplement 2), although success was not differ-
ent (44% vs 38%, respectively; P = .86). Sixty-six of the
patients (15.6%) received inodilators, without any significant
difference between groups.
When considering the whole group of 424 patients
independently of fluid responsiveness status, lactate levels
were significantly lower at 48 hours and 72 hours in the
peripheral perfusion group than in the lactate group (mean
difference, −0.36 mmol/L [95% CI, −0.62 to −0.09]; P = .01
in the peripheral perfusion group vs −0.34 mmol/L [95% CI,
−0.57 to −0.10] in the lactate group; P < .01), although there
were no statistically significant differences at 2, 4, 8, and 24
hours (eTable 2 in Supplement 2). CRT values were sig-
nificantly lower at 4, 8, and 24 hours in the peripheral
perfusion group compared with the lactate group (differ-
ence between medians, −0.45 seconds [95% CI, −0.78 to
−0.12]; P = .01 at 4 hours, −0.55 [95% CI, −0.85 to −0.25];
P < .01 at 8 hours, −0.42 [95% CI, −0.71 to −0.13]; P < .01 at
24 hours), with no statistically significant differences at 2,
48, and 72 hours. Evolution of CRT and lactate levels exclu-
sively in fluid unresponsive patients is shown in eTable 5 in
Supplement 2.
Central venous oxygen saturation and central venous–
arterial PCO2 gradients were not significantly different
between groups (eTable 2 and eFigure 4 in Supplement 2).
Other parameters are shown in eTable 2 in Supplement 2.
Primary Outcome
By day 28, a total of 74 patients (34.9%) in the peripheral
perfusion group and 92 (43.4%) in the lactate group
had died (hazard ratio, 0.75 [95% CI, 0.55 to 1.02]; P = .06;
risk difference, −8.5% [95% CI, −18.2% to 1.2%]) (Table 2
and Figure 2). There was no evidence of violation of the
proportional hazards assumption (Grambsch and Therneau
test P = .07).
Secondary and Tertiary Outcomes
There was significantly less organ dysfunction at 72 hours af-
ter randomization in the peripheral perfusion group (mean dif-
ference in SOFA score, −1.00 [95% CI, −1.97 to −0.02]; P = .045)
(Table 2). There were no significant between-group differ-
ences in the other 6 secondary outcomes (Table 2).
Patients in the peripheral perfusion group received less re-
suscitation fluids within the first 8 hours (mean difference,
−408 mL [95% CI, −705 to −110]; P = .01) (Table 2).
Twelve cases of suspected unexpected serious adverse re-
actions were reported by centers, without differences be-
tween groups, but none was considered as likely related to the
study protocol.
Subgroup and Sensitivity Analyses
Results of the prespecified subgroup analysis are reported
in Figure 3. Treatment effect on the primary outcome was
heterogeneous according to baseline SOFA subgroups
(P = .03 for interaction). Among patients with SOFA score
less than 10, the hazard ratio for 28-day mortality was 0.46
(95% CI, 0.27 to 0.78), whereas among patients with SOFA
score 10 or greater the hazard ratio was 0.98 (95% CI, 0.66
to 1.44). There were no significant differences in treatment
effect in the other prespecified subgroup analyses. There
was also no evidence of heterogeneity of treatment effects
across sites (eFigure 5 in Supplement 2). Estimates of treat-
ment effect on 28-day mortality from the prespecified sen-
sitivity analysis (frailty Cox model) were similar to those
from the main analysis.
Post Hoc Analysis
Estimates of treatment effect for several post hoc sensitivity
analyses, including per protocol analyses, were also similar to
the main analysis (eTable 6 in Supplement 2). There was no
evidence of heterogeneity of treatment effects across sites
(eFigure 5 in Supplement 2). In a post hoc analysis consider-
ing all SOFA measurements during the first 72 hours, there was
significantly less organ dysfunction among patients in the pe-
ripheral perfusion group compared with the lactate group
(mean difference, −1.16 [95% CI, −1.96 to −0.36]; P = .01)
(Figure 4).
Discussion
In this multicenter randomized clinical trial involving pa-
tients with early septic shock, a peripheral perfusion–
targeted resuscitation strategy did not result in a signifi-
cantly lower 28-day mortality when compared with a lactate
level–targeted strategy.
The study protocol operationalized, in a stepwise fash-
ion, interventions for septic shock resuscitation widely rec-
ommended by current guidelines1,5 or consensus/expert
recommendations.2,26 The small but significant differences
found in some protocol-related interventions suggest that
targets were actively pursued according to the assigned
group. The protocol was applied in a context of heteroge-
neous multinational ICUs with few registered violations,
but its potential generalizability requires further studies.
Fluid administration was based on fluid responsiveness
status during the intervention period15 and directed by
repeated evaluation of the respective assigned targets. In
this sense, peripheral perfusion–targeted resuscitation
resulted in a small but significant difference in resuscitation
fluids, which is consistent with recent observations14 and
could merit further exploration in the context of increasing
awareness of the risks of fluid overload. In contrast to previ-
ous studies,27 fluid responsiveness was determined in more
than 80% of the patients. The participation of only highly
committed centers with experience in assessment of fluid
responsiveness might have contributed to this.
Increasing MAP to levels of 80 to 85 mm Hg in patients
with chronic hypertension has been recommended by
recent guidelines and expert opinions.1,2 This recommenda-
tion was operationalized in the vasopressor test when CRT
or lactate targets were not reached. The increase in MAP
resulted in the achievement of the respective resuscitation
target in about 40% of patients in both study groups. These
results could provide a basis for further exploring the use of
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higher MAP targets in patients with septic shock and a his-
tory of chronic hypertension.
Peripheral perfusion–targeted resuscitation was associ-
ated with beneficial effects on the secondary outcome of
SOFA score at 72 hours and lower 28-day mortality in the pre-
defined subgroup of patients with less severe organ dysfunc-
tion at baseline. These results are in line with those
from some observational studies that showed that normal-
ization of peripheral perfusion after initial resuscitation
was associated with lower mortality and less organ dys-
function9-11 and from a pilot study that suggested that re-
striction of fluid resuscitation based on normal peripheral
perfusion was associated with improvement in organ
dysfunction.14 Because of the exploratory nature of such sec-
ondary outcomes and analyses, these findings should be con-
firmed by further research.
The use of CRT in clinical practice is not devoid of prob-
lems. CRT is dependent on age, sex, ambient temperature















(95% CI) P Value
Primary Outcome
Death within 28 d, No. (%) 74 (34.9) 92 (43.4) −8.5 (−18.2 to 1.2)b HR, 0.75 (0.55 to 1.02)a .06a
Secondary Outcomes
Death within 90 d, No. (%) 87 (41.0) 99 (46.7) −5.7 (−15.6 to 4.2)b HR, 0.82 (0.61 to 1.09)a .17a
Mechanical ventilation–free days
within 28 d, mean (SD)c
14.6 (12.1) 12.7 (12.2) 1.9 (−0.6 to 4.3) .14
Renal replacement therapy–free days
within 28 d, mean (SD)c
18.5 (12.1) 16.9 (12.1) 1.7 (−1.5 to 4.8) .31
Vasopressor-free days within 28 d,
mean (SD)c
16.7 (12.0) 15.1 (12.3) 1.6 (−0.7 to 3.9) .18
SOFA at 72 h, No.d 165 166 .045
Mean (SD) 5.6 (4.3) 6.6 (4.7) −1.00 (−1.97 to −0.02)
ICU length of stay, mean (SD), de 9.1 (9.8) 9.0 (9.6) 0.1 (−1.7 to 2.0) .91
Hospital length of stay,
mean (SD), df
22.9 (28.8) 18.3 (19.0) 4.6 (0.0 to 9.1) .05
Exploratory Outcomes
Amount of resuscitation fluids
within the first 8 h, No.
206 209
Mean (SD), mL 2359 (1344) 2767 (1749) −408 (−705 to −110) .01
Total fluid balance, mLg
Within 8 h, No. 198 205
Mean (SD) 1587 (1388) 1874 (1756) −288 (−598 to 22.0) .07
Within 24 h, No. 176 185
Mean (SD) 2025 (2181) 2343 (2336) −318 (−785 to 149) .18
Within 48 h, No. 153 160
Mean (SD) 992 (1810) 1224 (3336) −233 (−831 to 366) .45
Within 72 h, No. 157 162
Mean (SD) 1389 (2809) 1601 (3069) −212 (−858 to 434) .52
Intra-abdominal hypertension,
No. of events/total (%)h
75/119 (63.0) 68/120 (56.7) 6.4 (−6.9 to 19.6) RR, 1.11 (0.90 to 1.37) .36i
Use of renal replacement therapy,
No. (%)
30 (14.2) 42 (19.8) −5.7 (−13.3 to 1.9) RR, 0.71 (0.47 to 1.10) .15i
In-hospital mortality, No. (%) 84 (39.6) 97 (45.8) −6.1 (−16.0 to 3.7) RR, 0.87 (0.69 to 1.08) .20i
Abbreviations: HR, hazard ratio; ICU, intensive care unit; RR, risk ratio;
SOFA, Sequential Organ Failure Assessment.
a Hazard ratio (95% CI) and P value calculated with Cox proportional hazards
model with adjustment for baseline values of Acute Physiology and Chronic
Health Evaluation II score, SOFA score, lactate levels, capillary refill time,
and source of infection.
b Absolute difference (95% CI) calculated from Cox proportional hazard model
without adjustment for covariates.
c Treatment effects on mechanical ventilation, renal replacement therapy,
and vasopressor use assessed with zero inflated negative binomial models.
d Treatment effect calculated with linear regression adjusting for baseline
SOFA score.
e Treatment effects on ICU stay, hospital stay, and resuscitation fluids assessed
with generalized linear models with gamma distribution.
f Patients still in the hospital for 90 days or more after randomization were
considered to be discharged alive at day 90.
g Fluid balance within 8, 24, and 72 hours was calculated as all intravenous fluids
minus urine output and gastrointestinal losses from randomization to the
specified time point. Treatment effect on total fluid balance was calculated
with linear regression.
h Defined as an intra-abdominal pressure equal or higher than 12 mm Hg.
Intra-abdominal pressure was measured via the bladder, with instillation
of 25 mL of sterile saline at end-expiration in the complete supine position,
with transducer zeroed at the level of the mid-axillary line.
i From Fisher exact test.
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and light, and pressure applied during the maneuver—all
factors that might influence results.28-30 Although no rela-
tionship between CRT and hypovolemia was found in older
studies,31 more recent studies performed in critically ill
patients, including those with septic shock, have shown
clinically relevant associations with outcome.9-11,19,32 More
importantly, CRT was used as a measure of tissue perfusion
rather than a surrogate for macrohemodynamics.
The issue of interrater reliability is controversial.33 How-
ever, objective CRT measurements obtained by trained ICU
physicians using a chronometer revealed good interrater
reliability,11,12 contrasting with unreliable observations when
CRT was subjectively measured.34 To reduce inaccuracies, a
standardized procedure adopting a CRT of 3 seconds as nor-
mal was used according to recent clinical observations.11
Limitations
This study has several limitations. First, the nonblinded
design might have introduced bias. However, a primary out-
come not subject to observer bias was used. In addition,
Figure 3. Risk of Death Within 28 Days in the Prespecified Subgroups Among Patients Treated With Peripheral Perfusion–Targeted Resuscitation








Hazard Ratio (95% CI)








37/85 (43.5) 41/88 (46.6)>4 0.82 (0.52-1.28)
37/127 (29.1) 51/124 (41.1)≤4 0.70 (0.46-1.07)
APACHE II
32/130 (24.6) 49/135 (36.3)<25 0.61 (0.39-0.96)
42/82 (51.2) 43/77 (55.8)≥25 0.90 (0.59-1.38)
SOFA
21/103 (20.4) 42/107 (39.3)<10 0.46 (0.27-0.78)
53/109 (48.6) 50/105 (47.6)≥10 0.98 (0.67-1.45)
Confirmed source of infection
25/61 (41) 26/59 (44.1)No 0.84 (0.48-1.45)
49/151 (32.5) 66/153 (43.1)Yes 0.71 (0.49-1.03)
Lactate decrease from admission to baseline measurement, %
64/181 (35.4) 80/171 (46.8)≤10 0.73 (0.53-1.02)






The area of the square representing the hazard ratio is proportional to the
number of events in each subgroup. Horizontal bars represent 95% CI. P values
are for heterogeneity of treatment effect on the primary outcome in each
subgroup. Hazard ratios and 95% CIs were calculated with Cox proportional
hazards model adjusted for the baseline covariates Acute Physiology and
Chronic Health Evaluation (APACHE) II score,23 Sequential Organ Failure
Assessment (SOFA) score,24 lactate level, capillary refill time, and source of
infection. P values were calculated with treatment × subgroup interaction
terms. See Table 1 notes for APACHE II and SOFA definitions.
Figure 2. Kaplan-Meier Estimates of Cumulative Mortality Within 28 Days Among Patients Treated






































































Hazard ratio, 0.75 (95% CI, 0.55-1.02); P = .06
Hazard ratio, 95% confidence
interval, and P value were calculated
with a Cox proportional hazards
model that included as covariates
baseline Acute Physiology and
Chronic Health Evaluation (APACHE)
II score,23 Sequential Organ Failure
Assessment (SOFA) score,24 lactate
level, capillary refill time, and source
of infection. Median follow-up for
peripheral perfusion–targeted
resuscitation was 28 days
(interquartile range, 8-28 days) and
for lactate level–targeted
resuscitation was 28 days
(interquartile range, 6-28 days).
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several measurements were taken to minimize potential
cross-treatments, including intensive training, auditing, and
periodic reinforcement of the study procedures. At the end,
adherence and major violations were not different between
groups (eTable 3 in Supplement 2). Second, the study may
have been underpowered to exclude a clinically meaningful
difference between groups. In fact, this is the first major
interventional trial testing the potential role of CRT as a
resuscitation target, and therefore no previous data to facili-
tate a power calculation were available. Thus, the estimated
effect of peripheral perfusion–targeted resuscitation and the
sample size calculation were based mainly on small observa-
tional studies and might have been subject to error. Third,
interrater variability for CRT was not evaluated; nevertheless,
personnel at all centers were thoroughly trained to assess
CRT using a standardized technique. Fourth, randomization
was not stratified by sites. Therefore, imbalances in the allo-
cation to the treatment groups within sites may have
occurred by chance. However, this may have a small or null
effect on the effect estimates, since the results of the sensi-
tivity analysis with the frailty Cox model, which consider
within-site effects, were consistent with those from the main
analysis. Fifth, while the protocol used might appear com-
plex, it only operationalizes interventions widely recom-
mended by current guidelines into a stepwise protocol. Sixth,
since this was an ICU-based study, it does not provide infor-
mation on how effective this approach might be in other con-
texts, such as wards or resource-limited settings.
Conclusions
Among patients with septic shock, a resuscitation strategy tar-
geting normalization of capillary refill time, compared with a
strategy targeting serum lactate levels, did not reduce all-
cause 28-day mortality.
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This post hoc analysis is a mixed linear regression considering patient as random
effect and adjusting for baseline Sequential Organ Failure Assessment (SOFA)
score. P < .001 for mean SOFA score treatment × time interaction within 72
hours. Organ dysfunction assessed by SOFA score23 at baseline and 8, 24, 48,
and 72 hours after randomization. SOFA scores range from 0 to 24, with higher
scores indicating a greater severity of organ dysfunction and risk of death.23
Box plots indicate 75th percentile (top edge of box), 25th percentile (bottom
edge of box), and 50th percentile (bold horizontal line in box); whiskers indicate
minimum and maximum values up to 1.5 times the interquartile range from the
quartiles; circles indicate values that exceed 1.5 times the interquartile range.
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